Pro-Dex (PDEX) Set to Post Earnings on Thursday

Key Points

• Pro-Dex is expected to report Q1 2027 results after Thursday’s market close. Analysts anticipate earnings of $0.67 per share on revenue of $20.40 million, with the earnings call scheduled for October 30, 2026.
• The company’s previous quarter exceeded expectations, posting $0.87 EPS versus the $0.67 consensus and $20.41 million in revenue versus estimates of $19.20 million.
• Analyst sentiment remains positive, with a consensus “Buy” rating and a $74 price target, although company insiders sold 22,300 shares worth approximately $1.35 million during the past quarter.

Pro-Dex (NASDAQ:PDEX - Get Free Report) is expected to be announcing its Q1 2027 results after the market closes on Thursday, October 29th. Analysts expect the company to post earnings of $0.67 per share and revenue of $20.40 million for the quarter. Individuals may review the information on the company's upcoming Q1 2027 earnings report page for the latest details on the call scheduled for Friday, October 30, 2026 at 4:00 PM ET.

Pro-Dex (NASDAQ:PDEX - Get Free Report) last issued its earnings results on Thursday, September 3rd. The medical instruments supplier reported $0.87 earnings per share for the quarter, topping the consensus estimate of $0.67 by $0.20. The firm had revenue of $20.41 million for the quarter, compared to analyst estimates of $19.20 million. Pro-Dex had a return on equity of 25.13% and a net margin of 17.62%. On average, analysts expect Pro-Dex to post $3.09 EPS for the current fiscal year and $3.36 EPS for the next fiscal year.

Pro-Dex Stock Performance

PDEX stock opened at $60.56 on Thursday. The company has a debt-to-equity ratio of 0.28, a quick ratio of 2.45 and a current ratio of 4.10. The stock has a market capitalization of $195.61 million, a price-to-earnings ratio of 17.73 and a beta of 0.04. Pro-Dex has a 1 year low of $25.59 and a 1 year high of $77.00. The stock's fifty day moving average is $65.67 and its two-hundred day moving average is $61.51.

Insider Buying and Selling at Pro-Dex

In other news, CEO Kirk Richard Lee Van, Jr. sold 19,235 shares of the business's stock in a transaction on Wednesday, September 9th. The stock was sold at an average price of $60.58, for a total value of $1,165,256.30. Following the sale, the chief executive officer owned 79,993 shares of the company's stock, valued at approximately $4,845,975.94. The trade was a 19.38% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Alisha Charlton sold 2,300 shares of the company's stock in a transaction on Wednesday, September 9th. The shares were sold at an average price of $61.30, for a total value of $140,990.00. Following the completion of the sale, the chief financial officer owned 21,870 shares of the company's stock, valued at approximately $1,340,631. This trade represents a 9.52% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 22,300 shares of company stock worth $1,351,657. 48.00% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on PDEX shares. Weiss Ratings upgraded shares of Pro-Dex from a "hold (c+)" rating to a "buy (b)" rating in a research report on Thursday, October 8th. Ascendiant Capital Markets lifted their price objective on shares of Pro-Dex from $70.00 to $74.00 and gave the company a "buy" rating in a research report on Friday, September 11th. Finally, Zacks Research upgraded Pro-Dex from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, September 15th. One analyst has rated the stock with a Strong Buy rating and two have issued a Buy rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Buy" and a consensus target price of $74.00.

About Pro-Dex

Pro-Dex, Inc is a medical device company that designs, develops and manufactures powered surgical instruments and related equipment. Its products are primarily used in orthopedic, dental and other surgical procedures, where precision, reliability and controlled power are important.

The company supplies instruments and components to original equipment manufacturers and other medical device customers. Its capabilities include product design and development, engineering, manufacturing, assembly and related support services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.